RSC Advances



CORRECTION



Cite this: RSC Adv., 2020, 10, 13552

DOI: 10.1039/d0ra90029j

rsc.li/rsc-advances

Correction: Paclitaxel prodrug based mixed micelles for tumor-targeted chemotherapy

Dongyang Tang,^a Xin Zhao,^b Tie Yang^c and Cheng Wang^{*d}

Correction for 'Paclitaxel prodrug based mixed micelles for tumor-targeted chemotherapy' by Dongyang Tang *et al.*, *RSC Adv.*, 2018, **8**, 380–389.

The authors regret that in Fig. 4C, the image of the SM group with FA pretreatment was mistakenly a repeated version of the image of the SM group without FA pretreatment. The correct figure is included in this correction. This correction does not affect the scientific validity of the article.




Fig. 4 The *in vitro* cellular uptake analysis of SMs and MMs in the Hela cells. (A) The inverted fluorescence microscope images of the cells incubated with the C6-loaded SMs and MMs for 2 and 4 h. Scale bar: 200 μ m. (B) Flow cytometric analysis of mean fluorescence intensity in the cells treated with the C6-loaded SMs and MMs for 2 and 4 h. (C) Inverted fluorescence microscope images of the cells incubated with the C6-loaded SMs and MMs with or without the FA pretreatment 4 h. Scale bar: 200 μ m. The data are shown as mean \pm S.D. (n = 3). (D) Flow cytometric analysis of mean fluorescence intensity in the cells treated with the C6-loaded SMs and MMs with or without the FA pretreatment 4 h.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

[&]quot;Department of Experimental Center, Henan Institute of Science and Technology, Xinxiang, Henan 453003, P. R. China

^bDepartment of Pharmacy, Xinxiang Central Hospital, Xinxiang, Henan 453000, P. R. China

^{&#}x27;Nanjing Research Center, Jiangsu Chiatai Tianqing Pharmaceutical Co. Ltd, Nanjing, Jiangsu 210042, P. R. China

^aCollege of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China. E-mail: 11519016@zju.edu.cn